MedTrace Logo

PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

NCT00281619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2013-12-19

No results posted yet for this study

Summary

The purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose. The results may lead to better dosing based on individual needs.

Conditions

  • Kidney Transplant

Interventions

DRUG

CellCept (mycophenolate mofetil)

BEHAVIORAL

Dietary Monitoring

BEHAVIORAL

Drug Diary

PROCEDURE

Blood Sampling

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Alexander A. Vinks, PharmD., PhD · Children's Hospital Medical Center, Cincinnati

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00281619 on ClinicalTrials.gov